A Phase Ib/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
A Phase Ib/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Santa Monica, California 90404, United States
Hackensack, New Jersey 07601, United States
Chuo-ku, Tokyo 104-0045, Japan
Amsterdam, North Holland 1066 CX, Netherlands
Gangnam-Gu, Seoul Teugbyeolsi 06351, South Korea
Songpa-Gu, Seoul Teugbyeolsi 05505, South Korea